ADC Therapeutics ADCT Income Statement (2019-2026)

NYSE ADCT
$0.96 -0.07 (-6.80%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
13.15M46.50M17.29M76.32M18.99M19.28M14.49M18.05M17.41M18.46M23.03M18.84M16.43M20.85M19.25M
Cost of Revenue (Quarter)
0.50M0.53M2.27M1.29M0.59M1.32M0.37M2.51M1.22M0.85M2.06M0.84M1.20M3.47M2.10M
Gross Profit (Quarter)
12.64M45.97M15.03M75.03M18.40M17.96M14.13M15.54M16.19M17.61M20.97M18.00M15.22M17.38M17.14M
Operating items
Research & Development (Quarter)
36.80M48.95M48.54M41.68M39.48M31.34M27.08M25.73M24.30M32.50M28.93M30.09M26.80M19.88M17.37M
Selling, General & Administrative (Quarter)
16.59M19.01M18.24M19.62M15.14M12.00M9.62M12.03M10.24M10.00M9.96M8.82M8.33M9.90M9.70M
Restructuring Costs (Quarter)
13.09M0.38M2.67M
Other Operating Expenses (Quarter)
17.55M18.90M19.93M18.14M15.94M15.59M13.94M13.90M11.92M11.52M12.61M10.98M11.89M16.32M14.92M
Operating Expenses (Quarter)
70.94M86.86M86.70M79.44M70.56M58.93M50.64M51.67M46.45M54.03M51.50M62.99M47.40M46.10M44.66M
Operating Income (Quarter)
-57.79M-40.36M-69.41M-3.11M-51.57M-39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M-25.41M
EBIT (Quarter)
-57.79M-26.00M-40.36M-69.41M-3.11M-14.90M-51.57M-39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M-25.41M
Non-operating items
Non Operating Investment Income (Quarter)
-6.94M
Interest & Investment Income (Quarter)
0.02M18.31M0.02M0.27M2.30M2.37M2.70M2.95M3.25M3.44M2.05M1.93M2.47M1.99M1.82M
Other Non Operating Income (Quarter)
-13.61M22.53M12.88M-48.20M17.47M0.04M-5.07M0.86M5.23M-2.60M2.75M1.62M-0.74M0.20M-0.18M0.93M-0.98M2.63M20.54M
Non Operating Income (Quarter)
-9.36M13.44M12.88M-37.12M-0.00M-13.00M-9.25M-12.14M-6.67M-8.05M-9.97M-11.24M-10.00M-7.72M8.85M
Net income details
EBT (Quarter)
-71.40M-35.52M-17.83M-65.32M-51.32M-18.15M-59.69M-52.70M-45.40M-45.80M-35.71M-43.62M-38.44M-55.39M-40.97M-32.97M-16.57M
Tax Provisions (Quarter)
0.14M-1.17M-0.95M-0.71M-0.26M-4.50M-0.10M0.20M0.23M0.09M0.17M1.25M
Profit After Tax (Quarter)
-71.55M-34.38M-16.66M-64.37M-50.61M-25.48M-59.53M-48.92M-46.73M-86.95M-46.61M-36.54M-43.97M-32.06M-38.60M-56.65M-40.97M-6.41M-32.97M-16.57M
Income from Continuing Operations (Quarter)
-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M-16.57M
Consolidated Net Income (Quarter)
-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M-16.57M
Income towards Parent Company (Quarter)
-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M-16.57M
Net Income towards Common Stockholders (Quarter)
-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M-16.57M
Additional items
EPS (Basic) (Quarter)
-0.93-0.46-0.22-0.84-0.65-0.23-0.74-0.59-0.55-0.56-0.38-0.42-0.36-0.50-0.30-0.21-0.11
EPS (Diluted) (Quarter)
-0.23-0.74-0.59-0.55-0.56-0.38-0.42-0.36-0.50-0.30-0.21-0.11
Shares Outstanding (Quarter)
76.74M76.75M76.82M76.91M78.37M78.15M80.81M81.47M82.26M81.71M82.55M95.69M104.82M97.16M107.20M113.74M136.45M127.07M154.14M155.02M
Shares Outstanding (Diluted) (Quarter)
78.15M80.81M81.47M82.26M81.71M82.55M95.69M104.82M97.16M107.20M113.74M136.45M127.07M154.14M155.02M
Shares Outstanding (Entity) (Quarter)
76.74M78.27M76.82M76.91M78.37M89.04M89.04M89.04M89.04M89.04M89.04M99.45M99.45M101.61M101.76M115.08M115.19M128.31M129.73M127.44M
EBITDA (Quarter)
-57.79M-26.00M-40.36M-69.41M-3.11M-14.90M-51.57M-39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M-25.41M
Interest Expenses (Quarter)
4.26M9.52M9.22M8.80M11.36M3.25M10.42M10.31M12.82M34.89M12.50M12.68M13.12M3.76M12.23M13.00M13.39M-24.15M12.35M13.51M
Tax Rate (Quarter)
-0.20%6.56%1.45%1.39%0.44%8.54%0.22%-0.44%-0.66%-0.21%-0.43%-2.26%